C4 Therapeutics, Inc. (CCCC) Reports In-Line Q2 EPS

C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q2 EPS of ($0.36), in-line with the analyst estimate of ($0.36). Revenue for the quarter came in at $12 million versus the consensus estimate of $4.78 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Berenberg Starts Brooks Macdonald Group PLC (BRK:LN) at Buy
• Raymond James Upgrades Aecon Group (ARE:CN) (AEGXF) to Outperform